481 related articles for article (PubMed ID: 8996128)
1. MYCN oncogene amplification in neuroblastoma is associated with worse prognosis, except in stage 4s: the Italian experience with 295 children.
Tonini GP; Boni L; Pession A; Rogers D; Iolascon A; Basso G; Cordero di Montezemolo L; Casale F; Pession A; Perri P; Mazzocco K; Scaruffi P; Lo Cunsolo C; Marchese N; Milanaccio C; Conte M; Bruzzi P; De Bernardi B
J Clin Oncol; 1997 Jan; 15(1):85-93. PubMed ID: 8996128
[TBL] [Abstract][Full Text] [Related]
2. [The prognostic effect of amplification of the MYCN oncogene in neuroblastoma. The preliminary results of the Italian Cooperative Group for Neuroblastoma (GCINB)].
Pession A; De Bernardi B; Perri P; Mazzocco K; Rondelli R; Nigro M; Iolascon A; Forni M; Basso G; Conte M
Pediatr Med Chir; 1994; 16(3):211-8. PubMed ID: 7971442
[TBL] [Abstract][Full Text] [Related]
3. MYCN gene amplification is a powerful prognostic factor even in infantile neuroblastoma detected by mass screening.
Iehara T; Hosoi H; Akazawa K; Matsumoto Y; Yamamoto K; Suita S; Tajiri T; Kusafuka T; Hiyama E; Kaneko M; Sasaki F; Sugimoto T; Sawada T
Br J Cancer; 2006 May; 94(10):1510-5. PubMed ID: 16670717
[TBL] [Abstract][Full Text] [Related]
4. N-Myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 study. Neuroblastoma Study Group of the Société Francaise d'Oncologie Pédiatrique.
Rubie H; Hartmann O; Michon J; Frappaz D; Coze C; Chastagner P; Baranzelli MC; Plantaz D; Avet-Loiseau H; Bénard J; Delattre O; Favrot M; Peyroulet MC; Thyss A; Perel Y; Bergeron C; Courbon-Collet B; Vannier JP; Lemerle J; Sommelet D
J Clin Oncol; 1997 Mar; 15(3):1171-82. PubMed ID: 9060561
[TBL] [Abstract][Full Text] [Related]
5. Analysis of the relationship between MYCN gene and serum NSE and urinary VMA levels and neuroblastoma pathological features and prognosis.
Zhang H; He X; Miao Q; Li L; Song J; Jiang X
Cell Mol Biol (Noisy-le-grand); 2024 Apr; 70(4):134-139. PubMed ID: 38678619
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic and prognostic markers in infants with disseminated neuroblastoma: a retrospective analysis from the Italian Cooperative Group for Neuroblastoma.
Di Cataldo A; Dau D; Conte M; Parodi S; De Bernardi B; Giuliano M; Pession A; Viscardi E; Luksch R; Castellano A; Bertuna G; Haupt R;
Med Sci Monit; 2009 Jan; 15(1):MT11-8. PubMed ID: 19114976
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of MYCN oncogene expression in childhood neuroblastoma.
Bordow SB; Norris MD; Haber PS; Marshall GM; Haber M
J Clin Oncol; 1998 Oct; 16(10):3286-94. PubMed ID: 9779703
[TBL] [Abstract][Full Text] [Related]
8. Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study.
Schmidt ML; Lal A; Seeger RC; Maris JM; Shimada H; O'Leary M; Gerbing RB; Matthay KK
J Clin Oncol; 2005 Sep; 23(27):6474-80. PubMed ID: 16116154
[TBL] [Abstract][Full Text] [Related]
9. Relationship of DDX1 and NAG gene amplification/overexpression to the prognosis of patients with MYCN-amplified neuroblastoma.
Kaneko S; Ohira M; Nakamura Y; Isogai E; Nakagawara A; Kaneko M
J Cancer Res Clin Oncol; 2007 Mar; 133(3):185-92. PubMed ID: 17028906
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of MYCN amplification and ploidy in favorable-stage neuroblastoma: a report from the Children's Oncology Group.
Schneiderman J; London WB; Brodeur GM; Castleberry RP; Look AT; Cohn SL
J Clin Oncol; 2008 Feb; 26(6):913-8. PubMed ID: 18281664
[TBL] [Abstract][Full Text] [Related]
11. Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study.
George RE; London WB; Cohn SL; Maris JM; Kretschmar C; Diller L; Brodeur GM; Castleberry RP; Look AT
J Clin Oncol; 2005 Sep; 23(27):6466-73. PubMed ID: 16116152
[TBL] [Abstract][Full Text] [Related]
12. New definition of low-risk neuroblastoma using stage, age, and 1p and MYCN status.
Simon T; Spitz R; Faldum A; Hero B; Berthold F
J Pediatr Hematol Oncol; 2004 Dec; 26(12):791-6. PubMed ID: 15591897
[TBL] [Abstract][Full Text] [Related]
13. MYCN-status in neuroblastoma: characteristics of tumours showing amplification, gain, and non-amplification.
Spitz R; Hero B; Skowron M; Ernestus K; Berthold F
Eur J Cancer; 2004 Dec; 40(18):2753-9. PubMed ID: 15571958
[TBL] [Abstract][Full Text] [Related]
14. MYCN protein expression as a predictor of neuroblastoma prognosis.
Chan HS; Gallie BL; DeBoer G; Haddad G; Ikegaki N; Dimitroulakos J; Yeger H; Ling V
Clin Cancer Res; 1997 Oct; 3(10):1699-706. PubMed ID: 9815553
[TBL] [Abstract][Full Text] [Related]
15. [Study on MYCN gene amplification and CD44 expression in neuroblastoma].
Hu HL; He LJ
Zhonghua Bing Li Xue Za Zhi; 2004 Aug; 33(4):332-6. PubMed ID: 15363318
[TBL] [Abstract][Full Text] [Related]
16. Hormonal activity may predict aggressive behavior in neuroblastoma.
Zambrano E; Reyes-Múgica M
Pediatr Dev Pathol; 2002; 5(2):190-9. PubMed ID: 11910515
[TBL] [Abstract][Full Text] [Related]
17. Enlarged and prominent nucleoli may be indicative of MYCN amplification: a study of neuroblastoma (Schwannian stroma-poor), undifferentiated/poorly differentiated subtype with high mitosis-karyorrhexis index.
Kobayashi C; Monforte-Munoz HL; Gerbing RB; Stram DO; Matthay KK; Lukens JN; Seeger RC; Shimada H
Cancer; 2005 Jan; 103(1):174-80. PubMed ID: 15549714
[TBL] [Abstract][Full Text] [Related]
18. Proliferation marker KI-S5 discriminates between favorable and adverse prognosis in advanced stages of neuroblastoma with and without MYCN amplification.
Krams M; Hero B; Berthold F; Parwaresch R; Harms D; Rudolph P
Cancer; 2002 Feb; 94(3):854-61. PubMed ID: 11857322
[TBL] [Abstract][Full Text] [Related]
19. MYCN expression is not prognostic of adverse outcome in advanced-stage neuroblastoma with nonamplified MYCN.
Cohn SL; London WB; Huang D; Katzenstein HM; Salwen HR; Reinhart T; Madafiglio J; Marshall GM; Norris MD; Haber M
J Clin Oncol; 2000 Nov; 18(21):3604-13. PubMed ID: 11054433
[TBL] [Abstract][Full Text] [Related]
20. Chromosome band 11q23 deletion predicts poor prognosis in bone marrow metastatic neuroblastoma patients without MYCN amplification.
Yue ZX; Xing TY; Gao C; Liu SG; Zhao W; Zhao Q; Wang XS; Jin M; Ma XL
Cancer Commun (Lond); 2019 Nov; 39(1):68. PubMed ID: 31685009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]